Page last updated: 2024-11-11

ly 295427

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9823927
SCHEMBL ID304336
MeSH IDM0279583

Synonyms (13)

Synonym
SPECTRUM5_002039
ly 295427
SCHEMBL304336
ly-295427
ly295427
cholestan-3-ol, 4-(2-propenyl)-, (3alpha,4alpha,5alpha)-
(3alpha,4alpha,5alpha)-4-(2-propenylcholestan-3-ol)
152755-31-2
(3r,4s,5s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-4-prop-2-enyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol
CS-0092180
AKOS040752779
HY-125544
PD129412

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In this model, there is a dose-response for cholesterol lowering with an approximate ED50 value of 40 mg/kg/day and an inverse relationship between serum cholesterol and serum LY295427 levels."( Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters.
Archer, RA; Bean, JS; Beavers, LS; Bensch, WR; Breau, AP; Eacho, PI; Gadski, RA; Kauffman, RF; McClure, DB; Murphy, AT; Perry, DN; Schmidt, RJ, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (36.36)18.2507
2000's5 (45.45)29.6817
2010's2 (18.18)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.81 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]